vs
莫德纳（MRNA）与北极星（PII）财务数据对比。点击上方公司名可切换其他公司
北极星的季度营收约是莫德纳的1.6倍（$1.7B vs $1.0B），北极星净利率更高（-2.8% vs -19.7%，领先16.8%），北极星同比增速更快（8.0% vs -45.4%），北极星自由现金流更多（$-342.5M vs $-880.0M），过去两年北极星的营收复合增速更高（-8.0% vs -45.0%）
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
北极星公司（Polaris Inc.）是总部位于美国明尼苏达州麦地那的机动车制造企业，创立于明尼苏达州罗索，当地目前仍保留其工程研发与生产设施。公司曾通过胜利摩托子公司生产摩托车，2011年收购印第安摩托品牌后转由该子公司运营摩托业务，此前还曾生产私人水上摩托艇产品。
MRNA vs PII — 直观对比
营收规模更大
PII
是对方的1.6倍
$1.0B
营收增速更快
PII
高出53.4%
-45.4%
净利率更高
PII
高出16.8%
-19.7%
自由现金流更多
PII
多$537.5M
$-880.0M
两年增速更快
PII
近两年复合增速
-45.0%
损益表 — Q3 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $1.7B |
| 净利润 | $-200.0M | $-47.2M |
| 毛利率 | 79.6% | 20.2% |
| 营业利润率 | -25.6% | — |
| 净利率 | -19.7% | -2.8% |
| 营收同比 | -45.4% | 8.0% |
| 净利润同比 | -1638.5% | 29.2% |
| 每股收益（稀释后） | $-0.51 | $-0.83 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MRNAPII
| Q1 26 | — | $1.7B | ||
| Q4 25 | — | $1.9B | ||
| Q3 25 | $1.0B | $1.8B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $966.0M | $1.8B | ||
| Q3 24 | $1.9B | $1.7B | ||
| Q2 24 | — | $2.0B |
净利润MRNAPII
| Q1 26 | — | $-47.2M | ||
| Q4 25 | — | $-303.6M | ||
| Q3 25 | $-200.0M | $-15.8M | ||
| Q2 25 | — | $-79.3M | ||
| Q1 25 | — | $-66.8M | ||
| Q4 24 | $-1.1B | $10.6M | ||
| Q3 24 | $13.0M | $27.7M | ||
| Q2 24 | — | $68.7M |
毛利率MRNAPII
| Q1 26 | — | 20.2% | ||
| Q4 25 | — | 20.0% | ||
| Q3 25 | 79.6% | 20.7% | ||
| Q2 25 | — | 19.4% | ||
| Q1 25 | — | 16.0% | ||
| Q4 24 | 23.5% | 20.4% | ||
| Q3 24 | 72.4% | 20.6% | ||
| Q2 24 | — | 21.6% |
营业利润率MRNAPII
| Q1 26 | — | — | ||
| Q4 25 | — | -16.7% | ||
| Q3 25 | -25.6% | 1.1% | ||
| Q2 25 | — | -0.7% | ||
| Q1 25 | — | -2.4% | ||
| Q4 24 | -129.0% | 3.7% | ||
| Q3 24 | -3.8% | 3.8% | ||
| Q2 24 | — | 6.1% |
净利率MRNAPII
| Q1 26 | — | -2.8% | ||
| Q4 25 | — | -15.8% | ||
| Q3 25 | -19.7% | -0.9% | ||
| Q2 25 | — | -4.3% | ||
| Q1 25 | — | -4.3% | ||
| Q4 24 | -115.9% | 0.6% | ||
| Q3 24 | 0.7% | 1.6% | ||
| Q2 24 | — | 3.5% |
每股收益（稀释后）MRNAPII
| Q1 26 | — | $-0.83 | ||
| Q4 25 | — | $-5.34 | ||
| Q3 25 | $-0.51 | $-0.28 | ||
| Q2 25 | — | $-1.39 | ||
| Q1 25 | — | $-1.17 | ||
| Q4 24 | $-2.91 | $0.18 | ||
| Q3 24 | $0.03 | $0.49 | ||
| Q2 24 | — | $1.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.1B | $282.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $9.3B | $750.4M |
| 总资产 | $12.1B | $5.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MRNAPII
| Q1 26 | — | $282.0M | ||
| Q4 25 | — | $138.0M | ||
| Q3 25 | $1.1B | $335.5M | ||
| Q2 25 | — | $324.3M | ||
| Q1 25 | — | $291.7M | ||
| Q4 24 | $1.9B | $287.8M | ||
| Q3 24 | $1.6B | $291.3M | ||
| Q2 24 | — | $322.7M |
总债务MRNAPII
| Q1 26 | — | — | ||
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.6B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $2.1B |
股东权益MRNAPII
| Q1 26 | — | $750.4M | ||
| Q4 25 | — | $828.4M | ||
| Q3 25 | $9.3B | $1.1B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $10.9B | $1.3B | ||
| Q3 24 | $11.9B | $1.3B | ||
| Q2 24 | — | $1.3B |
总资产MRNAPII
| Q1 26 | — | $5.2B | ||
| Q4 25 | — | $4.9B | ||
| Q3 25 | $12.1B | $5.3B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.5B | ||
| Q4 24 | $14.1B | $5.5B | ||
| Q3 24 | $15.8B | $5.6B | ||
| Q2 24 | — | $5.7B |
负债/权益比MRNAPII
| Q1 26 | — | — | ||
| Q4 25 | — | 1.82× | ||
| Q3 25 | — | 1.13× | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | — | 1.32× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | — | 1.29× | ||
| Q2 24 | — | 1.56× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-847.0M | — |
| 自由现金流经营现金流 - 资本支出 | $-880.0M | $-342.5M |
| 自由现金流率自由现金流/营收 | -86.6% | -20.6% |
| 资本支出强度资本支出/营收 | 3.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-1.9B | $168.0M |
8季度趋势，按日历期对齐
经营现金流MRNAPII
| Q1 26 | — | — | ||
| Q4 25 | — | $178.7M | ||
| Q3 25 | $-847.0M | $158.8M | ||
| Q2 25 | — | $320.3M | ||
| Q1 25 | — | $83.2M | ||
| Q4 24 | $825.0M | $206.3M | ||
| Q3 24 | $-1.6B | $21.0M | ||
| Q2 24 | — | $146.3M |
自由现金流MRNAPII
| Q1 26 | — | $-342.5M | ||
| Q4 25 | — | $114.0M | ||
| Q3 25 | $-880.0M | $116.7M | ||
| Q2 25 | — | $279.8M | ||
| Q1 25 | — | $47.6M | ||
| Q4 24 | $303.0M | $137.3M | ||
| Q3 24 | $-1.7B | $-32.4M | ||
| Q2 24 | — | $79.1M |
自由现金流率MRNAPII
| Q1 26 | — | -20.6% | ||
| Q4 25 | — | 5.9% | ||
| Q3 25 | -86.6% | 6.3% | ||
| Q2 25 | — | 15.1% | ||
| Q1 25 | — | 3.1% | ||
| Q4 24 | 31.4% | 7.8% | ||
| Q3 24 | -92.2% | -1.9% | ||
| Q2 24 | — | 4.0% |
资本支出强度MRNAPII
| Q1 26 | — | — | ||
| Q4 25 | — | 3.4% | ||
| Q3 25 | 3.2% | 2.3% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | 54.0% | 3.9% | ||
| Q3 24 | 8.1% | 3.1% | ||
| Q2 24 | — | 3.4% |
现金转化率MRNAPII
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 19.46× | ||
| Q3 24 | -120.46× | 0.76× | ||
| Q2 24 | — | 2.13× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
PII
暂无分部数据
